Scarica l'app Stockscreener
3.35
3.46%
-0.12
Dopo l'orario di chiusura:
3.37
0.02
+0.60%
Precedente Chiudi:
$3.47
Aprire:
$3.37
Volume 24 ore:
2.39M
Relative Volume:
0.74
Capitalizzazione di mercato:
$607.61M
Reddito:
$4.03M
Utile/perdita netta:
$-198.37M
Rapporto P/E:
-2.6693
EPS:
-1.255
Flusso di cassa netto:
$-158.74M
1 W Prestazione:
-9.70%
1M Prestazione:
+6.35%
6M Prestazione:
-17.28%
1 anno Prestazione:
-13.88%
Intervallo 1D:
$3.31
$3.42
Intervallo di 1 settimana:
$3.29
$3.86
Portata 52W:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.35 | 629.38M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Iniziato | Oppenheimer | Outperform |
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - marketbeat.com
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7%What's Next? - marketbeat.com
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - marketbeat.com
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView
PRME Q2 2026 Earnings: Narrower-than-Expected Loss Marks Progress as Stock SlipsProfit Announcement - vinanet.vn
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat
Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - MarketBeat
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - MarketBeat
PRME Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.57% Stock AdvanceGuidance Downgrade Alert - vinanet.vn
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Nigeria
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Prime Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine Q2 net loss narrows on lower expenses - TradingView
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary - TradingView
PRME: Regulatory advances and cost reductions position pipeline for key clinical milestones in 2027 - TradingView
FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME) - stocktitan.net
Prime Medicine reports Q2 2026 net loss $42.1M, cash $108.8M; IND/CTA clearances for PM577a - TradingView
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24 - TradingView
Prime Medicine (PRME) Slides 3.3% as Gene Editing Sector Faces Renewed CautionRSI Overbought Alerts - vinanet.vn
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):